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Abstract
Background: Understanding the key characteristics of malaria testing and treatment is essential to the control of
a disease that continues to pose a major risk of morbidity and mortality in mainland Tanzania, with evidence of a
resurgence of the disease in recent years. The introduction of artemisinin combination therapy (ACT) as the first-line
treatment for malaria, alongside policies to promote rational case management following testing, highlights the need
for evidence of anti-malarial and testing markets in the country. The results of the most recent mainland Tanzania
ACTwatch outlet survey are presented here, including data on the availability, market share and price of anti-malarials
and malaria diagnosis in 2016.
Methods: A nationally-representative malaria outlet survey was conducted between 18th May and 2nd July, 2016.
A census of public and private outlets with potential to distribute malaria testing and/or treatment was conducted
among a representative sample of administrative units. An audit was completed for all anti-malarials, malaria rapid
(RDT) diagnostic tests and microscopy.
Results: A total of 5867 outlets were included in the nationally representative survey, across both public and private
sectors. In the public sector, availability of malaria testing was 92.3% and quality-assured (QA) ACT was 89.1% among all
screened outlets. Sulfadoxine–pyrimethamine (SP) was stocked by 51.8% of the public sector and injectable artesunate
was found in 71.4% of all screened public health facilities. Among anti-malarial private-sector stockists, availability of testing was 15.7, and 65.1% had QA ACT available. The public sector accounted for 83.4% of the total market share for malaria
diagnostics. The private sector accounted for 63.9% of the total anti-malarial market, and anti-malarials were most commonly distributed through accredited drug dispensing outlets (ADDOs) (39.0%), duka la dawa baridi (DLDBs) (13.3%) and
pharmacies (6.7%). QA ACT comprised 33.1% of the national market share (12.2% public sector and 20.9% private sector).
SP accounted for 53.3% of the total market for anti-malarials across both private and public sectors (31.3 and 22.0% of the
total market, respectively). The median price per adult equivalent treatment dose (AETD) of QA ACT in the private sector
was $1.40, almost 1.5 times more expensive than the median price per AETD of SP ($1.05). In the private sector, 79.3% of
providers perceived ACT to be the most effective treatment for uncomplicated malaria for adults and 88.4% perceived this
for children.
Conclusions: While public sector preparedness for appropriate malaria testing and case management is showing
encouraging signs, QA ACT availability and market share in the private sector continues to be sub-optimal for most outlet types. Furthermore, it is concerning that SP continues to predominate in the anti-malarial market. The reasons for this
remain unclear, but are likely to be in part related to price, availability and provider knowledge or preferences. Continued
efforts to implement government policy around malaria diagnosis and case management should be encouraged.
Keywords: Quality-assured artemisinin combination therapy, ACT, Rapid diagnostic testing, Anti-malarial markets
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Background
Following declines in malaria prevalence in the first decade of the twenty first century, more recent data from
mainland Tanzania have shown evidence of a resurgence in the disease. Among children under five, malaria
prevalence halved from 18 to 9% between 2007–2008
and 2011–2012, but has since risen to 14%. There is also
regional variation, with prevalence as high as 28% in the
Western zone [1]. Ninety-three percent of mainland Tanzania’s population resides in malaria-endemic areas, and
in 2015 there were estimated to be 7.3 million clinical and
confirmed cases of malaria reported in the country [2].
Tanzania Mainland’s Strategic Plan for Malaria 2015–
2020, includes goals to (1) reduce malaria illness and
deaths by 80.0% from 2012 levels; (2) reduce malaria
prevalence to 1.0%; and, (3) increase the proportion of
pregnant women receiving two or more doses of sulfadoxine–pyrimethamine (SP) during pregnancy to 80.0%
[3]. Malaria case management priorities are: to improve
the quality of diagnostic and case management services;
to maintain and improve anti-malarial drug supplies in
the public sector; to improve access to quality and affordable artemisinin combination therapy (ACT) in the private sector. The strategy further outlines specific areas of
focus that will support these targets, including strengthening the supply chain, information provision and behaviour change communications (BCC) to promote universal
diagnostic coverage and uptake of ACT.
The 2014 Tanzania Mainland’s National Guidelines
for the Diagnosis and Treatment of Malaria stipulate
artemether–lumefantrine (AL) as the first-line treatment for uncomplicated malaria in both adults and children, with dihydroartimisinin-piperaquine (DHA PPQ)
as a second-line treatment in cases of treatment failure
[4]. The guidelines were also updated to align with the
World Health Organization (WHO) recommendations
stipulating injectable (IV/IM) artesunate for treatment
of patients with severe malaria, and a three-course treatment of SP for intermittent treatment as prevention
during pregnancy (IPTp) (rather than a two-course treatment as previously recommended). According to the
2014 National Guidelines, patients with severe malaria
should be referred to a public health facility. Quinine is
the second-line treatment for cases of uncomplicated
malaria contra-indicated for ACT and for women in the
first trimester of pregnancy, or in cases of severe malaria
not responding to first-line treatment. The 2014 National
Guidelines also advocate parasitological confirmation of
suspected malaria cases for all ages in mainland Tanzania. Since 2006, oral artemisinin monotherapy has been
banned [5].
Mainland Tanzania has implemented several strategies
in recent years to improve access to confirmatory testing
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and first-line ACT treatment. For example, between 2007
and 2013, the mainland Tanzanian public sector received
93.1 million doses of AL [3]. Between 2009 and 2012, a
phased roll-out of malaria rapid diagnostic tests (RDTs)
to all levels of government health facilities was implemented to complement microscopy services, with
national coverage in 2013 [6]. This was in line with growing recognition that relatively inexpensive and sensitive
RDTs could be made available at the most peripheral levels of the public health sector.
In 2010, mainland Tanzania participated in the
Affordable Medicines Facility-malaria (AMFm) pilot,
administrated by the Global Fund, with the aim of
increasing access to ACT and reducing use of artemisinin monotherapy in the public and private sector [7]. ACT that achieved accredited status from the
WHO, European Medicines Authority (EMA) or the
Global Fund (termed quality assured [QA] ACT) were
subsidized at ‘factory gate’ before entering the supply
chains in countries involved in the project. AMFmsubsidized products carried a ‘green leaf ’ logo to differentiate them from non-subsidized and non-QA
ACT products [8]. Following the AMFm pilot period
in 2010–2011, the subsidy mechanism transitioned
into a new model called the private sector co-payment
mechanism (CPM) which continued to fund ACT subsidies in the private sectors of many malaria-endemic
countries, including mainland Tanzania [8, 9]. The
CPM focused exclusively on the private sector supply of QA ACT given that an independent evaluation
showed that the AMFm had greater impact on the supply of QA ACT in the private than the public sector
[10]. The public sector continued to receive subsidized
ACT through an alternative Global Fund mechanism,
and QA ACT medicines in this sector were not marked
with the ‘green leaf ’ logo.
In the 12 month period prior to data collection
reported here, 7.3 million treatment doses were delivered in mainland Tanzania during the CPM period,
representing a decline from the AMFm peak—where
21.6 million doses were delivered in 2012 (personal communication, Global Fund). The CPM period was further
marked by a reduction in the level of subsidy to first-line
ACT buyers—from over 90% during the AMFm period to
70%~ in 2016. During the CPM period in mainland Tanzania, there was an absence of any provider or consumer
behaviour change communication or other supporting
interventions to increase awareness of the subsidized,
QA ACT (personal communication, Global Fund).
Several other initiatives have focused on improving
malaria case management services in the private sector. Following the loosening of laws in mainland Tanzania in 1991 that had previously banned the provision of
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medical services in the private sector, there was a proliferation and diversification of private providers [11]. A
large proportion of outlets were registered (but essentially unregulated) private medicine dispensing outlets,
including small drug shops called duka la dawa baridi
(DLDBs) (sometimes referred to as Part II drug outlets)
[12]. According to the national policy, DLDBs are only
permitted to sell non-prescription medications [13].
However, in practice they frequently dispensed prescription-only treatments. In 2003, the mainland Tanzanian
government introduced the accredited drug dispensing outlet (ADDO) programme, which aimed to provide
accreditation to these outlets, through a programme of
training and support to increase their capacity to provide
quality primary health services, particularly in remote
areas [14]. As part of the accreditation process, ADDO
providers received training on malaria case management
and malaria national treatment guidelines [13]. ADDOs
are permitted to sell prescription medicines, including
ACT, while referring any cases of severe malaria to a public health facility. Since a successful 2012 pilot initiative
introducing testing with RDTs in ADDOs, efforts have
been made to begin a national roll-out of RDTs in these
outlets. There are over 4000 ADDOs located mainly in
rural areas [15], and thought to be another 2000 outlets
awaiting accreditation by the government nationally.
Understanding the anti-malarial and malaria diagnostic
supply side will be an important means to inform future
case management strategies and guide programmes
aimed at improving adherence to national guidelines.
Since 2010, ACTwatch has been implementing outlet
surveys in mainland Tanzania to generate timely, relevant
and high quality evidence about anti-malarial markets for
policy makers, donors and implementing organizations
[16]. In 2016, ACTwatch implemented its final survey in
mainland Tanzania. The objective of this paper is to provide practical evidence to inform strategies and policies
in mainland Tanzania towards achieving national malaria
control goals. The paper describes the total market for
malaria medicines and diagnostics at national level.

Methods
Design and sampling

The 2016 mainland Tanzania outlet survey was a nationally representative, cross-sectional, quantitative survey conducted among a sample of outlets stocking
anti-malarial medicines and diagnostics. The survey was
implemented between 18 May and 2 July, 2016. This was
the fourth such survey conducted in mainland Tanzania.
Detailed ACTwatch project and methodological information have been published elsewhere [16, 17]. Briefly,
all potential outlet types stocking anti-malarials and
diagnostics in mainland Tanzania in both public and
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private sectors were included in the study. According to
the ACTwatch methodology, outlets are included in the
survey if they have the ‘potential’ to sell or distribute
anti-malarials or diagnostic testing. This includes outlets
that may not typically be expected to stock anti-malarial
medicines, such as general retailers, village shops, or
itinerant drug vendors. However, it is recognized that in
many countries these outlets can operate as vendors for
anti-malarial commodities, either illegally or/and outside
of the formal health system. These outlets are included in
the sample as a means to confirm their role or presence
in a given country’s anti-malarial and diagnostic market.
These outlets may differ on a country-by-country basis,
but broad categories are used to define public and private
sector outlets.
Outlets sampled in the public sector included public health facilities (e.g., the national referral hospital,
regional hospitals, district hospitals, health centres, dispensaries), and private not-for-profit facilities [including
non-governmental organizations (NGOs) hospitals and
clinics, faith-based hospitals, clinics]. The private-sector
outlet types sampled were private for-profit health facilities (including private hospitals, clinics, diagnostic laboratories), pharmacies (which are registered and licensed
by a national regulatory authority, and staffed by pharmacists and qualified health practitioners), ADDOs (drug
stores that primarily sell medicines, registered with a
national regulatory authority, where staff have received
training), DLDBs (drug stores that primarily sell medicines, with no formal licensing, and no guarantee of staff
training), general retailers (grocery stores and village
shops), and itinerant drug vendors (mobile, unregistered
providers selling medicines).
The primary sampling approach taken for ACTwatch
outlet surveys entails sampling a set of administrative
units (geographic clusters) with a population of approximately 10,000 to 15,000 inhabitants. Clusters are selected
with cluster probability of selection proportionate to size
(PPS). The most appropriate administrative unit in mainland Tanzania matching the desired population size was
at the ward level.
Clusters (wards) were selected using probability proportional to population size sampling, using data from
the 2012 Tanzania Population and Housing Census [18].
Additional wards were selected for oversampling of public health facilities, private for-profit health facilities,
pharmacies, and ADDOs. This booster sampling strategy
was used to obtain a sufficient sample size for indicator estimates within these outlet types. The sample was
stratified by urban–rural ward designation. In total, 58
wards were selected for the main census sample (28 rural,
30 urban) and a further 172 wards were selected for the
booster sample (84 rural, 88 urban).
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Within each selected cluster a census of all outlet types
with the potential to provide anti-malarials or diagnostics
to consumers was undertaken. The inclusion criteria for
outlets were: (1) one or more anti-malarials in stock on
the day of the survey; (2) one or more anti-malarials in
stock in the three months preceding the survey; and, (3)
malaria blood testing (RDTs or microscopy) available.

DroidDB software was used to complete an audit of all
anti-malarials and RDTs as well as a provider interview.
Quality control measures implemented during the fieldwork included questionnaire review by supervisors. Up
to 20% of all outlets were also checked by quality controllers to verify the interview had been completed.

Sample size

The 2016 outlet survey protocol received ethical approval
from the national ethical approval board in mainland Tanzania (Reference number: NIMR/HQ/R.8a/
Vol. IX/2209). Provider interviews and product audits
were completed only after administration of a standard
informed consent form and provider consent to participate in the study. Providers had the option to end the
interview at any point during the study. Standard measures were employed to maintain provider confidentiality
and anonymity.

The study was powered to detect a minimum of a 20%
point change in availability of QA ACT among antimalarial stockists between each round and within each
domain for each survey, at the 5% significance level with
80% power. The number of study clusters was calculated
for each research domain based on the required number of anti-malarial stockists and assumptions about the
number of anti-malarial stockists per cluster. Sample size
requirements for the 2016 survey were calculated using
information from the 2014 survey round including antimalarial and QA ACT availability, outlet density per cluster, and design effect.
Training and fieldwork

Fieldworker training consisted of standardized classroom
presentations and exercises as well as a field exercise.
Examinations administered during training were used
to select field workers, supervisors and quality controllers. Additional training was provided for supervisors
and quality controllers focused on field monitoring, verification visits and census procedures. Fieldwork teams
were provided with a list of selected clusters and official
maps that illustrated administrative boundaries. In each
selected cluster, fieldworkers conducted a full enumeration of all the aforementioned outlet types. This included
enumeration of outlets with a physical location, as well
as identification of itinerant drug vendors using local
informants. To identify outlets, fieldworkers systematically walked through each cluster, looking for the outlets.
To distinguish between pharmacies, ADDOs and DLDBs,
fieldworkers were trained to look for licenses hanging up
on the wall and to prompt providers for any clarification,
especially when these licenses were not legible. In mainland Tanzania, pharmacies have licenses clearly displayed
above counters, and ADDOs have a specific license that
include a logo to recognise the outlet as part of the programme. The primary provider/owner of each outlet was
invited to participate in the study and the screening questions were administered to assess anti-malarial and diagnostic availability.
Interviews were conducted in Swahili using questionnaires that were translated from English to Swahili and
back to English to confirm translations. A structured
questionnaire programmed into mobile phones using

Protection of human subjects

Measures

The outlet survey questionnaire included an audit of all
available anti-malarial medicines and RDTs. Providers were asked to show the interviewer all anti-malarial
medicines and RDTs currently available. A product audit
sheet captured information for each unique product in
the outlet, including formulation, brand name, active
ingredients and strengths, package size, manufacturer
and country of manufacture for anti-malarials, and brand
name, manufacturer, country of manufacture, antigens
and parasite species for RDTs. Providers were asked to
report the retail and wholesale price for each product as
well as the amount distributed to individual consumers in
the last week.
Data analysis and indicators

Data were analysed using Stata (StataCorp College Station, TX, USA). Standard indicators were constructed
according to definitions applied across the ACTwatch
project, descriptions of which have been provided in
detail elsewhere [9, 11]. Anti-malarials identified during the outlet drug audit were classified according to
information on drug formulation, active ingredients and
strengths as non-artemisinin therapy, artemisinin monotherapy and ACT. Non-artemisinin therapy was classified as SP or other non-artemisinin therapy. Although no
longer indicated for malaria case management, SP is still
recommended for IPTp. Artemisinin monotherapy was
further classified as oral and non-oral, the latter including
medicines recommended for first-line treatment of severe
malaria. ACT was classified as QA ACT or non-qualityassured ACT. QA ACT were ACT granted World Health
Organization (WHO) prequalification, ACT in compliance with the Global Fund Quality Assurance Policy, on
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the Global Fund list of approved pharmaceutical products
for procurement, or ACT granted regulatory approval by
the European Medicines Agency (EMA). Classification
was completed by matching product audit information
(formulation, active ingredients, strengths, manufacturer,
country of manufacture, package size) to lists of approved
medicines from the WHO, EMA and Global Fund.
QA ACT availability in the public sector was among
all outlets screened, while in the private sector it was
restricted to those outlets that had anti-malarials in
stock. Anti-malarial market share, or the relative distribution of the anti-malarials to individual consumers
recorded in the drug audit, was standardized to allow
for meaningful comparisons between anti-malarials
with different treatment courses and different formulations. The adult equivalent treatment dose (AETD) was
defined as the amount of active ingredient required to
treat an adult weighing 60 kg according to WHO treatment guidelines [19]. Provider reports on the amount of
the drug sold or distributed during the week preceding
the survey were used to calculate volumes according to
type of anti-malarial. The volume of each drug was calculated as the number of AETDs that were reported to
have been sold/distributed during the week preceding
the survey. Measures of volume included all dosage forms
to provide a complete assessment of anti-malarial market
share. Diagnostic market share was calculated from the
number of malaria blood tests (i.e., microscopy and RDT)
performed or distributed by outlet type as a proportion
of all tests performed or distributed in the previous week.
Median private sector price for one AETD was calculated for QA ACT and for the most popular non-artemisinin therapy, which in mainland Tanzania was SP
given it was the most common non-artemisinin therapy
distributed. The interquartile range (IQR) is displayed
as a measure of dispersion. Price data presented were
collected in local currencies and converted to US dollar prices (average exchange rate for the data collection
period). Price measures included tablet anti-malarials
only, given differences in unit costs for tablet and nontablet formulations. While all QA ACT are by definition
tablet formulations, SP may be available in other formulations including syrups and injections. These other formulations were excluded from median price calculations.
Provider knowledge was measured as the percentage
of providers who identified ACT as the most effective
treatment for uncomplicated malaria. This was measured
separately for adults and children, and is reported here by
outlet type; 95% confidence intervals provide an indicator
of the precision of the estimates.
Sampling weights were calculated as the inverse of the
probability of cluster selection. All point estimates were
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weighted using survey settings and all standard errors
calculated taking account of the clustered and stratified
sampling strategy with the relevant suite of survey commands in Stata. A finite population correction was also
applied to adjust standard errors, as a relatively large proportion of available clusters were selected for inclusion in
the sample.

Results
Sample description

A total of 5868 outlets were screened for availability of
anti-malarials and/or malaria blood testing services and
2,317 were subsequently interviewed. A total of 2194 outlets surveyed were found to have anti-malarials in stock
on the day of the survey, 39 had anti-malarials reportedly
in stock during the previous 3 months but not on the day
of the visit, and 84 had malaria blood testing available but
no antimalarials in stock (A more detailed breakdown
of outlet sample eligibility, by rural/urban strata may be
found in Additional file 1).
Availability

Table 1 shows the availability of anti-malarials and
malaria diagnosis among all screened public sector outlets. Across the public sector, 96.2% had any anti-malarial
on the day of the survey. QA ACT availability was 92.0%
among public health facilities and 65.8% among private
not-for-profit facilities. When disaggregated by pack size
(Additional file 2), availability of paediatric QA AL was
62.2% in public health facilities and 23.2% in private notfor-profit facilities. The availability of non-QA ACT was
13.3% in public health facilities and 29.8% in private notfor profit outlets. SP accounted for the majority of available non-artemisinin therapy, stocked by 51.8% of the
public sector. Injectable artesunate was found in 71.4%
of public health facilities and 24.9% private not-for-profit
facilities.
Malaria diagnostics were available in 91.8% of public health facilities (18.9% had microscopy and 89.3%
stocked RDTs) and in 97.1% of private not for-profit facilities (68.9% had microscopy and 89.3% had RDTs).
Across the public sector, availability of both QA ACT
and testing was 83.5%, and this was higher in public
health facilities (86.0%) than private not-for-profit facilities (62.9%).
In the private sector, among all screened outlets,
availability of any anti-malarial was highest among
pharmacies (99.2%; N = 61), ADDO (96.9%; N = 1503)
and DLDB (94.7%, N = 148). Of the 3541 general retailers screened, only 0.5% had anti-malarials in stock
(Additional file 3).Table 2 shows private sector availability of different types of anti-malarials among outlets
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with any anti-malarial in stock on the day of the survey.
Among anti-malarial stockists, 65.1% of the private sector had QA ACT available. In terms of availability of
different pack sizes, 52.7% had adult pack sizes of QA
AL in stock and 20.4% had paediatric QA AL (Additional file 4). Non-QA ACT was found in 42.9% of all
anti-malarial stocking private outlets. ACT was most
commonly available in anti-malarial stocking pharmacies (QA ACT 90.0%; non-QA ACT 98.7%). SP was the
most commonly available non-artemisinin therapy antimalarial in the therapy stocking private sector, and over
90% of pharmacies and ADDOs had SP in stock. Oral
quinine was also stocked by 64.6% of private sector outlets. Injectable artesunate was available in 34.4% of private for-profit health facilities and 17.9% of pharmacies,
but was otherwise largely absent from the private sector
(Table 2).
Malaria diagnosis was available among 15.7% of the
anti-malarial stocking private sector, and highest among
private for-profit facilities (96.0%), followed by pharmacies (21.9%), ADDOs (10.2%) and DLDBs (8.1%). Availability of malarial microscopy was 5.4%; availability of
RDTs was 14.3% in the private sector.
Price

The median price per AETD of QA ACT in the private
sector was $1.40, and almost 1.5 times more expensive
than the median price per AETD of SP ($1.05) (Table 3).
The median price per AETD of non-QA ACT was $4.65.
When disaggregated by outlet type, the price of these
three anti-malarials was usually lower in DLDBs than
other private outlet types (Additional file 5).

The median prices for malaria microscopy in the private
sector was $0.70 for an adult and $0.47 for children. The
median malaria RDT price for an adult and child was $0.93.
Anti‑malarial market share

The public sector accounted for 36.1% of all anti-malarial
volumes distributed in the week prior to the survey. Of
all anti-malarials distributed, 12.2% were QA ACT in the
public sector, with public sector SP accounting for a further 22.0% (Fig. 1).
The private sector accounted for 63.9% of the total antimalarial market, and anti-malarials were most commonly
distributed through ADDOs (39.0%), DLDBs (13.3%)
and pharmacies (6.7%). Of all the anti-malarials distributed, 29.7% were ACT in the private sector (QA ACTwith the logo, 13.5%; 7.4 QA ACT without the logo and
8.8% non-QA ACT). Most of the private sector ACT was
distributed through ADDOs (17.7%). SP was the most
commonly distributed anti-malarial in the private sector
(31.3%). Oral AMT was absent from the market in this
survey round.
The relative anti-malarial market share within outlet
type is shown in Additional file 6. Of note is the similarity
in anti-malarial mix between ADDOs and DLDBs, with
ACT making up 45.4 and 41.8% of their distributed antimalarials, respectively.
Diagnostic market share

The public sector accounted for 83.4% of the total market
share for malaria diagnostics (Fig. 2). Most of the diagnostic tests distributed across the public and private sector
were RDTs (90.2% of the total diagnostic market share).

Table 1 Availability of anti-malarials and malaria testing among all screened public sector outlets
Public health
facility % CI

Private not for-profit
facility % CI

Public sector
total % CI

N = 341

N = 65

N = 406

Any anti-malarial

96.2 (89.0, 98.8)

96.4 (79.5, 99.5)

96.2 (90.0, 98.6)

QA ACT

92.0 (84.0, 96.2)

65.8 (49.0, 79.4)

89.1 (82.5, 93.5)

non-QA ACT

13.3 (7.5, 22.5)

29.8 (17.1, 46.7)

15.1 (9.3, 23.6)

SP

51.5 (40.3, 62.6)

54.1 (36.9, 70.4)

51.8 (41.5, 61.9)

Oral Quinine

4.6 (1.8, 11.3)

51.4 (33.9, 68.6)

9.7 (6.3, 14.6)

Other non-artemisinin therapy (amodiaquine and
parenteral quinine)

9.7 (6.5, 14.2)

9.3 (3.7, 21.4)

9.7 (6.7, 13.9)

Artesunate injection

71.4 (62.9, 78.5)

24.9 (16.0, 36.6)

66.3 (57.8, 73.8)

Any malaria testing

91.8 (85.6, 95.4)

97.1 (80.6, 99.6)

92.3 (86.7, 95.7)

Malaria microscopy

18.9 (13.3, 26.2)

68.9 (54.1, 80.6)

24.3 (18.2, 31.8)

RDTs

89.3 (82.2, 93.7)

89.3 (77.4, 95.3)

89.3 (82.9, 93.4)

QA ACT and any malaria testing

86.0 (77.9, 91.5)

62.9 (46.4, 76.8)

83.5 (76.4, 88.8)

5.9 (2.8, 12.1)

2.9 (0.4, 19.4)

5.6 (2.7, 11.2)

QA ACT no malaria testing

ACTwatch Group et al. Malar J (2017) 16:202
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Table 2 Availability of anti-malarials and malaria testing among anti-malarial stocking private sector outlets
Private for-profit facility
% CI

Pharmacy % CI

ADDO % CI

DLDB % CI

Private sector
total % CI

N=118

N=60

N=1468

N=142

N=1800

QA ACT

73.6 (63.0, 82.0)

90.0 (75.0, 96.4)

66.3 (57.7, 74.0)

58.8 (42.8, 73.1)

65.1 (57.2, 72.3)

Non-QA ACT

66.5 (49.0, 80.4)

98.7 (94.2, 99.7)

43.3 (33.1, 54.1)

34.9 (21.3, 51.4)

42.9 (31.5, 55.1)

SP

76.8 (70.0, 82.4)

94.4 (90.2, 96.9)

92.2 (87.9, 95.0)

75.2 (62.2, 84.9)

86.3 (80.4, 90.6)

Oral quinine

63.9 (49.0, 76.6)

74.8 (61.7, 84.5)

65.2 (57.7, 72.1)

67.8 (51.5, 80.6)

64.6 (57.9, 70.8)

8.1 (3.9, 16.2)

0.7 (0.1, 3.4)

2.6 (1.3, 5.3)

6.1 (2.6, 14.0)

4.0 (2.3, 7.0)

Other non-artemisinin
therapy
IV/IM artesunate

34.4 (26.9, 42.9)

17.9 (5.6, 44.5)

N=120

N=61

N=1490

0.2 (0.1, 0.8)

N=146

0.0 (–)

N=1832

2.4 (1.4, 4.0)

Any test

96.0 (91.1, 98.3)

21.9 (12.8, 34.8)

10.2 (6.4, 15.9)

8.1 (3.9, 16.2)

15.7 (12.6, 19.4)

Microscopy

73.9 (51.0, 88.5)

8.8 (1.8, 34.3)

0.6 (0.2, 2.3)

0.0 (–)

RDT

78.5 (69.4, 85.4)

21.9 (12.8, 34.8)

9.7 (6.0, 15.3)

8.1 (3.9, 16.2)

5.4 (2.8, 10.3)
14.3 (11.4, 17.7)
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90
80
70
60
50
40
30
20
10
0

Public
Sector

Private
Sector

Private
for-Profit
Facility

Pharmacy

ADDO

Non-oral artemisinin monotherapy

Non QA ACT

Other non-artemisinin therapy

QA ACT without green leaf logo

SP

QA ACT with the green leaf logo

DLDB

General
Retailer

Inerant
Drug
Vendor

Fig. 1 Anti-malarial market share

Provider perceptions

Figure 3 shows the percentage of providers who reported
that ACT was the most effective treatment for uncomplicated malaria for adults and children. Providers in
the public sector perceived ACT as the most effective

treatment for uncomplicated malaria for adults and children (97.9 and 95.7%, respectively). In the private sector,
79.3% of providers perceived ACT to be the most effective treatment for uncomplicated malaria for adults and
88.4% perceived this for children. Almost one in five
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Table 3 Median private sector price (and IQRs) for antimalarials and malaria blood testing
N

Median price (USD)

IQR

QA ACT

2251

$1.40

[1.24–1.86]

Non-QA ACT

1381

$4.65

[1.5–6.25]

SP

4239

$1.05

[0.93–1.40]

88

$0.70

[0.47–0.93]

Microscopy (adult)

88

$0.47

[0.47–0.93]

RDT (adult)

Microscopy (child)

247

$0.93

[0.47–0.93]

RDT (child)

247

$0.93

[0.47–0.93]

providers working in ADDOs and DLDBs perceived that
ACT was not the most effective treatment for adults
(21.1 and 22.9%, respectively).

Discussion
This paper has provided a comprehensive overview of
the malaria testing and treatment landscape in mainland Tanzania in 2016, in both public and private sectors.
While the public sector shows strong readiness to adhere
to national guidelines, there is sub-optimal QA ACT
availability and market share in the private sector. There
is also persistent widespread distribution of SP, which
continues to predominate the anti-malarial market.
Public sector readiness for malaria case management

The results indicate that in terms of availability, the public sector’s level of readiness for appropriate malaria case
management is high. The National Malaria Strategic Plan
[3] aims for the provision of universal access to malaria

testing and first-line treatment, and these results indicate
that universal access has almost been achieved in this
sector. Almost every screened outlet in the public sector had QA ACT available and over 90% of public sector
outlets had either malaria microscopy or RDTs available,
reflecting several strategies implemented nationally since
2013 to scale up confirmatory testing in this sector. Only
a small fraction (5.6%) of outlets had QA ACT available without testing, and this signifies an improvement
since 2014 (where 9.5% of public sector outlets had QA
ACT but no testing) [20]. Furthermore, three-quarters
of public health facilities had injectable artesunate, the
first-line treatment for severe malaria, and this reflects
a substantial increase in the public sector since the previous survey round, from 21.3% in 2014 [20] to 66.3% in
2016. National efforts to align with the WHO recommendations for treatment of severe malaria are reflected in
these findings. The results for provider knowledge in the
public sector were also encouraging, and stand in contrast to a previous study that found overall poor levels of
knowledge of AL in this sector [21].
Despite these promising findings, there are some gaps
in public sector readiness for malaria case management
that require attention. Of concern is the finding that SP
was available in just over half of all screened outlets in
the public sector, meaning that much of the public sector
is not equipped to provide IPTp, although this reflects an
increase from 2011 and 2014 [22]. This is also in light of
several national strategies that have encouraged universal
coverage of IPTp during pregnancy and substantial rollout of IPTp3+ nationwide. The findings from the most
recent outlet survey suggest there are key challenges to
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Fig. 3 Provider perceptions of the most effective treatment for uncomplicated malaria

be addressed, including maintaining a constant supply of
SP across the public health sector. This will be important
to address in order to meet national targets that stipulate
80% coverage of IPTp by 2020.
In addition, despite widespread availability of QA ACT
and sub-optimal availability of SP, the market share findings illustrate that SP was more widely administered
than QA ACT in the public sector. QA ACT market
share within the public sector was also at its lowest level
since before the launch of the AMFm, only one in three
anti-malarials distributed in the public sector were a QA
ACT in 2016 compared to one in every two in 2010 [22].
These findings may reflect stock-outs of different pack
sizes of QA ACT. While the strength of all first-line AL
tablets for treatment of uncomplicated malaria is indeed
the same, the implementation of the AL policy includes
delivery of four different AL pack sizes (6, 12, 18 and 24
tablets) suitable for management of four different weight
categories of patients (5–14; 15–24; 25–34; ≥35 kg). In
the public sector, availability of the different weight categories was variable. For example, a pack size of 12 tablets of QA AL was available in less than half of the public
sector outlets. Providers may ration ACTs because of
uncertainty with supply coupled with availability of
non-recommended treatments [23]. Alternatively, this
may reflect an increase of RDTs in this sector and better
management of patients through confirmatory testing,
lending to a reduction of QA ACT market share. Other

population based evidence from mainland Tanzania
between 2010 and 2012 reported a significant decrease in
the percentage of people with fever obtaining ACT from
57.4 to 46.1%, along with an increase in the percentage of
people obtaining a blood test from 28.7 to 46.6% [24]. As
such, the market share findings from this outlet survey
may reflect increases in diagnostic coverage and better
management of patients.
The role of the private sector in malaria case management

In 2016, almost all pharmacies, ADDOs and DLDBs that
were screened were in the business of stocking malaria
commodities, as were around three-quarters of private
not for-profit facilities. Consistent with previous outlet surveys [20], general retailers are not typically antimalarial stockists. Of the 3540 screened outlets, only ten
had anti-malarials in stock in 2016. Market share data
also illustrate the importance of the private sector, which
accounted for 63.9% of the total anti-malarial market.
Anti-malarials in the private sector were also most commonly distributed through ADDOs.
The concentration of malaria commodities distributed
among ADDOs may reflect several strategies to license
DLDBs. Since 2003, the ADDO programme has been
implemented as a means to regulate and improve service
provision of health care in the private sector. The findings
from 2016 illustrate that ADDOs accounted for over 1468
anti-malarials stockists in the private sector compared to
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142 DLDBs, representing the greatest concentration of
private sector service delivery points for malaria. This
reflects a change in market composition from previous
surveys, where in 2010 most of the private sector antimalarial service delivery points were DLDBs (48% of
the total market composition) as compared to ADDOs
(20% of the market composition) [22]. These findings are
reflective of the several initiatives by the mainland Tanzania government over the years to scale up the ADDO
programme and increase coverage of regulated private sector outlets. As of 2015, between 4000 and 9000
DLDBs had been accredited, becoming ADDOs, nationally in mainland Tanzania [15].
Readiness and performance of the private sector
for malaria case management

Where anti-malarials were available in the private sector,
just over half of the anti-malarial stockists had QA ACT
available. Market share data also illustrated that in 2016
around 30% of the private sector market share comprised
ACT, reflecting an overall increase from 2010 [22]. Nonartemisinin therapy, typically SP, accounted for one-half
of all anti-malarials distributed. The availability of malaria
confirmatory testing was also very low in the private sector. This is corroborated by household survey data that
found only 2.1% of febrile children under five received
a confirmatory test in the private sector [24]. However,
where confirmatory testing was available, the results also
demonstrate that the median price of all malaria diagnostics was lower than QA ACT, which is encouraging as it
may provide a cost incentive for a patient to test before
treatment.
While ADDOs accounted for the largest distribution
of QA ACT, and comprised most of the market share
in the private sector, there was very little difference in
the anti-malarial mix across outlet types, given SP was
the most commonly dispensed anti-malarial across all
outlets. Lessons on how to maintain and improve ACT
availability and distribution among these outlet types
can be learnt from several studies that have investigated
factors which influence ADDO ACT stocking characteristics. Studies have found that ADDOs with greater
client load and which are in close proximity to other
outlets that sell ACT medicines, are more likely to stock
ACT as compared to isolated outlets which serve fewer
customers [25, 26]. Another determinant of ACT stocking practices among ADDOs has been the presence of
a licensed pharmacist [25, 26], and somewhat related
to this, staff retention. One study found that up to 40%
of trained ADDO dispensers were no longer working at
the outlet, and consequently other untrained staff were
employed lending to poor dispensing practices, irrational use of medicines, and even poorer performance
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than DLDBs [27]. Future strategies to improve the
retention rate of trained personnel at ADDOs will be
key to ensure the sustainability of an effective ADDO
programme and may want to consider the targeting
of busier outlets in competitive markets to encourage
faster uptake of ACT.
In addition to their role in the provision of anti-malarial medication, ADDOs are now permitted to perform
testing (using RDTs) for malaria. Nevertheless, there
is little to differentiate ADDOs from their unregulated
counterparts in terms of malarial blood testing availability, with RDT stocking levels languishing below 10%.
Indeed, this mirrors challenges documented in other
countries, where maintaining constant supply of RDTs
have been noted, as well as determining effective incentives for private providers and patients to use RDTs and
adhere to results [28]. Despite these challenges, several studies have documented the feasibility of including RDT testing in ADDOs. For example, a randomized
controlled trial to investigate whether the introduction
of RDTs among ADDOs improved malaria case management found that confirmatory diagnosis increased from
19 to 74% in intervention districts, which also resulted
in improved targeting of ACT to patients with malaria
[29]. Similar positive outcomes have been demonstrated
in other countries, [30, 31], with studies concluding
that private sector outlets can safely and correctly test
for malaria with appropriate training, supervision, and
record keeping [32]. Scaling up access to RDTs in the
private sector through ADDOs will be an important
initiative to improve levels of confirmatory testing and
treatment practices. Of promise is that the mainland
Tanzania National Strategic Plan includes strategies to
improve accessibility and affordability of RDTs by facilitating the procurement of quality diagnostic devices at
subsidized/low costs through the global partnership [3].
The findings from the 2016 study provide a benchmark
from which this can be measured.
Given evidence from this survey that ADDOs are the
most important private sector outlet in the provision of
anti-malarials, future strategies can target these outlets
as a means to disrupt the widespread distribution of SP
for case management, increase uptake of ACT and RDTs.
Future training and learning opportunities provide an
opportunity to emphasize the importance of adhering to
national treatment guidelines, address misconceptions
that SP is the most effective treatment for adults, and
ensure constant supply of QA ACT and RDTs to these
providers. In short, there is significant opportunity with
regard to the role that ADDOs play in the rationalization
of malaria treatment and diagnosis, particularly given
their predominance in the anti-malarial private sector
market and current efforts to engage with this sector.
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Market performance of the green leaf ACT logo

The results from the most recent survey illustrate that
the market share of ACT remained less than 50% and
ACT carrying the ‘green leaf ’ logo (a marker of subsidized QA ACT) was less than 15%. This also reflected
a decline from 2014 levels, which was the result of an
upward trend in market share since the introduction
of the subsidy mechanism [10]. These findings are perhaps not surprising considering the transition from a
dedicated donor funding during the AMFm period to a
country specific grant funding mechanism, which was
further amplified by a reduction in funding for co-paid
ACT. Indeed, the number of subsidized QA ACT doses
delivered to mainland Tanzania’s private sector through
the CPM was a third of what it was in 2012. Furthermore, the ACT price subsidy in 2016 was 70% compared to ~90% during the AMFm period, lending to an
increase in QA ACT price over the years [22] such that
the price of QA ACT was one and a half times that of SP
in 2016. In this context, the reduction in the green leaf
logo market share to the relatively low levels reported
in this paper may largely be explained by a more limited
supply and availability of these medications in the context of reduced funding and scaled down programming.
Furthermore, in the absence of supportive interventions,
including behaviour change communications designed
to increase awareness of the QA ACT with the logo, providers and consumers alike may have less awareness of
the first-line, subsidized treatment. Indeed, the results
from this study illustrated that in the private sector ACT
is still not universally perceived as the most effect treatment for uncomplicated malaria. Up to one in five providers continued to cite treatments that were not ACTs.
In absence of supportive interventions targeted at both
consumers and providers to raise awareness of affordable, quality, first-line treatment for malaria, behaviour
change will be challenging [33].
Availability and distribution of non‑QA ACT

In the private sector, availability and distribution of nonQA ACT was common. One in every three ACT medicines distributed were non-QA ACT, and distribution
was most common among private for-profit facilities
and pharmacies as compared to other private sector outlet types. This is of concern given that quality-assurance
status has been associated with high quality medicines in
drug quality studies [34]. In Tanzania, a nationally representative survey of over 1700 anti-malarials in the private
sector found that ACT samples lacking WHO prequalification were 25 times more likely to be of poor quality than those with WHO prequalification status [35],
illustrating how quality-assurance status can serve as an
important indicator of ACT drug quality.
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While public sector outlets may be required to obtain
particular drugs that meet certain quality standards,
quality may not necessarily be a factor in private sector
procurement decisions. This may in part explain why the
private sector was found to stock and distribute non-QA
ACT. What is of interest however is that non-QA ACT
was three times more expensive that QA ACT, yet it was
still being distributed, indicating that some consumers
were willing to pay over four USD for a treatment. This
raises the question of why consumers would pay more
for non-QA ACT when less expensive QA ACT are available. Non-QA ACT products were primarily available
and distributed by private for-profit facilities and pharmacies, which are more common anti-malarial service
delivery points in urban areas as compared to rural areas
in Tanzania [22]. As outlets located in urban areas typically serve consumers with a higher socio-economic status [22, 36], these consumers may be able to better afford
the relatively high price of non-QAACT. Or, this could
be related to a lack of awareness of subsidy programme,
given demand creation strategies had not been promoted
in the past several years. Indeed, a better understanding
of provider and consumer demand for QA ACT and nonQAACT will be important for developing strategies to
promote use of QA ACT over non-QA products.
Availability and use of SP

The results from the 2015 illustrate the widespread availability and distribution of SP, and this is a barrier to
implementation of the government policy for first-line
treatments for uncomplicated malaria. Furthermore,
while SP is mandated for use in IPTp, it seems likely
from these results that it is also being utilized more
widely than government policy recommends. Government efforts to encourage universal coverage of IPTp
during pregnancy may have driven increased demand
for SP, and there is some evidence that levels of IPTp
have increased in recent years [1]. However, while there
has been a substantial roll-out of IPTp3+ nationwide,
with parallel behaviour change communication and promotion through public health facilities, there is no evidence or policy documents suggesting that the private
sector should also play a role in the provision of this service in the country. Continued uses of SP likely include
management of fever/malaria in people of all ages given
the widespread availability and distribution of this
anti-malarial.
The substantial private sector SP market share is
cause for concern, and suggests it is being administered for malaria case management, against national
(and international) guidelines. This is also supported
by other evidence that suggests many SP products have
packaging and patient instructions indicating its use
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for uncomplicated malaria for all ages. Additional file 7
shows some example photographs of SP packaging collected during fieldwork, some of which clearly indicate that the product is appropriate for the treatment of
malaria for all ages. Other research in mainland Tanzania
has corroborated these findings and illustrated that SP
was predominantly distributed to men [37].
Limitations

The results presented in this study provided a cross-sectional snapshot of the anti-malarial testing and treatment
markets in mainland Tanzania in 2016. The ACTwatch
outlet survey design has limitations that have been documented and reported elsewhere [17, 38]. Limitations
specific to the mainland Tanzania study centre around
potential bias emerging from interviews with DLDBs,
for whom the practice of supplying prescription medications is not permitted. All vendors participating in this
study gave their informed consent to take part, and were
assured of their anonymity. It is feasible that vendors
may deflate or increase the levels of anti-malarial testing
or treatment that they are reporting. The use of an electronic data collection approach, while convenient from
a data collection perspective, may have had the effect
of arousing suspicion among the interviewees. In addition, the study was not designed or powered to compare
ADDOs and DLDBs, but it did provide an opportunity
to examine these outlet types and explore their performance. In addition, it is uncertain that these two outlet
types were substantively different, as DLDBs may have
begun, but not yet completed the accreditation process at
the time of the survey, or indeed may have competed the
process previously and then lost their accreditation.

Conclusion
Tanzania is in a unique position in that several strategies have been in place to improve malaria case management services and this paper provides a contemporary
understanding of mainland Tanzania’s anti-malarial landscape. Overall, mainland Tanzania’s public sector is well
prepared for malaria testing and treatment, with good
levels of provider knowledge. The private sector however appears to have several gaps in its preparedness,
which is reflective of reduced funding levels for the subsidy programme since the AMFm. QA ACT availability
and market share in the private sector continues to be
disappointing for most outlet types, and there is persistent widespread distribution of SP, which continues to
predominate in the market. The reasons for this remain
unclear, but are likely to be related to overall reduced
funding of the ACT subsidy programme, such that affordable and more widely available SP remains in favourable
competition to QA ACT. In the absence of supportive
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interventions, provider and consumer knowledge of the
first-line treatment are also a barrier. Government drives
for increased IPTp, while encouraging, are unlikely to
fully explain the high levels of SP distribution. Continued
efforts to implement government policy around malaria
diagnosis and case management should be encouraged.
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Additional file 5. Price for all private sector outlets.
Additional file 6. Antimalarial market share, within outlet type.
Additional file 7. SP product photographs from fieldwork.
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